Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Stone

Showing results (491-500 of 544) with videos related to

Pageof 55
Sort By:
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.
Leukemia|August 29, 2019
Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
British Journal of Haematology|February 5, 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemiaJulia Etchin, Takaomi Sanda, Marc R Mansour, et al.
Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.
Cancer Letters|November 26, 2025
Profiling the genomic landscape and evolutionary history of polyploid giant cancer cells in undifferentiated pleomorphic sarcomasAmy L Bowes, Sara Waise, Tom Lesluyes, et al.
Blood|June 10, 2011
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AMLElspeth M Payne, Niccolò Bolli, Jennifer Rhodes, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pageof 55

Showing results (491-500 of 544) with videos related to

Sort By:
Pageof 55
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.
Leukemia|August 29, 2019
Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
British Journal of Haematology|February 5, 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemiaJulia Etchin, Takaomi Sanda, Marc R Mansour, et al.
Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.
Cancer Letters|November 26, 2025
Profiling the genomic landscape and evolutionary history of polyploid giant cancer cells in undifferentiated pleomorphic sarcomasAmy L Bowes, Sara Waise, Tom Lesluyes, et al.
Blood|June 10, 2011
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AMLElspeth M Payne, Niccolò Bolli, Jennifer Rhodes, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pageof 55